BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol 2020;11:778. [PMID: 33473247 DOI: 10.3389/fneur.2020.00778] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Mirmosayyeb O, Ghaffary EM, Dehghan MS, Ghoshouni H, Bagherieh S, Barzegar M, Shaygannejad V. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review. J Cent Nerv Syst Dis 2023;15:117957352311678. [DOI: 10.1177/11795735231167869] [Reference Citation Analysis]
2 Masuda H, Mori M, Uzawa A, Uchida T, Muto M, Ohtani R, Aoki R, Kuwabara S. Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD. Sci Rep 2023;13:3538. [PMID: 36864239 DOI: 10.1038/s41598-023-30594-z] [Reference Citation Analysis]
3 Wang L, Dong L, Zhao M, Jiang C, Geng M, Li S, Xing J, Wang T. A case of EBV encephalomyelitis with positive anti-GFAP-IgG antibody with recurrent fever and dysuresia as the main symptoms: Case report and retrospective analysis. Medicine (Baltimore) 2022;101:e31995. [PMID: 36482607 DOI: 10.1097/MD.0000000000031995] [Reference Citation Analysis]
4 Xue H, Yang W, Zhao Y, Wang L, Wang G, Zhang M, Zhang H. Pain in neuromyelitis optic spectrum disorder. Mult Scler Relat Disord 2022;68:104192. [PMID: 36244188 DOI: 10.1016/j.msard.2022.104192] [Reference Citation Analysis]
5 Zhang X, Pei L, Xu Y, Zhang Y, Lu Z, Song S, Tian Y, Zhao X, Yin H, Wang W, Huang Y. Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2022;68:104213. [PMID: 36223704 DOI: 10.1016/j.msard.2022.104213] [Reference Citation Analysis]
6 Fadda G, Flanagan EP, Cacciaguerra L, Jitprapaikulsan J, Solla P, Zara P, Sechi E. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1011579] [Reference Citation Analysis]
7 Mewes D, Kuchling J, Schindler P, Khalil AAA, Jarius S, Paul F, Chien C. Diagnostik der Neuromyelitis-optica-Spektrum-Erkrankung (NMOSD) und der MOG-Antikörper-assoziierten Erkrankung (MOGAD). Klin Monbl Augenheilkd 2022;239:1315-1324. [DOI: 10.1055/a-1918-1824] [Reference Citation Analysis]
8 Orssaud C. Neuropathie optique héréditaire de Leber : le diagnostic différentiel. Journal Français d'Ophtalmologie 2022;45:S9-S16. [DOI: 10.1016/s0181-5512(22)00445-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kang H, Qiu H, Hu X, Wei S, Tao Y. Differences in Neuropathic Pain and Radiological Features Between AQP4-ON, MOG-ON, and IDON. Front Pain Res 2022;3:870211. [DOI: 10.3389/fpain.2022.870211] [Reference Citation Analysis]
10 Cooper SA, Leddy SG, Skipper NT, Barrett VJM, Plant GT. Optic neuritis with potential for poor outcome. Pract Neurol. [DOI: 10.1136/practneurol-2021-003228] [Reference Citation Analysis]
11 Lotan I, Romanow G, Levy M, Kister I. Is there a link between neuropathic pain and constipation in NMOSD and MOGAD? Results from an online patient survey and possible clinical implications. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mirmosayyeb O, Ghaffary EM, Bagherieh S, Barzegar M, Dehghan MS, Shaygannejad V. Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Racke MK, Frohman EM, Frohman T. Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes. Front Neurol 2021;12:799698. [PMID: 35095742 DOI: 10.3389/fneur.2021.799698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Novikova ES. Possibilities of therapy for neuromyelitis optica spectrum disorders. Rus ž det nevrol 2022;16:49-58. [DOI: 10.17650/2073-8803-2021-16-4-49-58] [Reference Citation Analysis]
15 Nie T, Blair HA. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. CNS Drugs 2022;36:1133-41. [PMID: 36070074 DOI: 10.1007/s40263-022-00949-7] [Reference Citation Analysis]
16 Contentti EC, Eizaguirre MB, López PA, Rojas JI, Tkachuk V, Alonso R. Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103647] [Reference Citation Analysis]
17 Serizawa K, Tomizawa-Shinohara H, Miyake S, Yogo K, Matsumoto Y. Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders. Inflamm Regen 2021;41:34. [PMID: 34724990 DOI: 10.1186/s41232-021-00184-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Meca-Lallana JE, Maurino J, Pérez-Miralles F, Forero L, Sepúlveda M, Calles C, Martínez-Ginés ML, González-Suárez I, Boyero S, Romero-Pinel L, Sempere ÁP, Meca-Lallana V, Querol L, Costa-Frossard L, Prefasi D, Gómez-Ballesteros R, Ballesteros J. Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire. PLoS One 2021;16:e0255317. [PMID: 34324586 DOI: 10.1371/journal.pone.0255317] [Reference Citation Analysis]
19 Bartels F, Lu A, Oertel FC, Finke C, Paul F, Chien C. Clinical and neuroimaging findings in MOGAD-MRI and OCT. Clin Exp Immunol 2021. [PMID: 34152000 DOI: 10.1111/cei.13641] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
20 Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T; Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. J Neurol Sci 2021;428:117546. [PMID: 34252701 DOI: 10.1016/j.jns.2021.117546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Aktas O, Kümpfel T. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]. Nervenarzt 2021;92:307-16. [PMID: 33728474 DOI: 10.1007/s00115-021-01098-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Duchow A, Bellmann-strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 2021;11:49-59. [DOI: 10.2217/nmt-2020-0046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
23 Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers 2020;6:85. [PMID: 33093467 DOI: 10.1038/s41572-020-0214-9] [Cited by in Crossref: 144] [Cited by in F6Publishing: 144] [Article Influence: 48.0] [Reference Citation Analysis]